

the POSNOC study

PARTICIPANT NEWSLETTER - FOURTH EDITION

September 2019



POSITIVE Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy

Hello

Welcome to the fourth edition of the POSNOC participant newsletter. Whether you have been part of the study from the start or have recently decided to take part, we hope you enjoy this newsletter and find it interesting and informative. So sit back, relax and have a read about everything we've been up to for the last few months.....




Celebrating 5 years of POSNOC!



POSNOC has just reached 5 years of recruitment. The first participant was randomised onto the study back in August 2014. We'd like to personally thank you all for your hard work and commitment to the study over the past five years. It's been amazing to see the study grow and to reach ever closer to answering this important question of finding out if armpit treatment is overtreatment.


Recruitment

We are pleased to announce that recruitment is going really well and we currently have 1491 participants on the study. We hope that we're able to maintain this level of recruitment to keep us on track to reach our target of 1900 participants by August 2021. It is really exciting to know we are well over half way through the recruitment period. But who will be the 1500th participant to join the study?



Recruitment continued

Where we are now




This bar graph shows how many participants have reached each time point within the study. It is vital we receive all the required data at each of these points. We would like to thank you for your continued commitment to completing all the study questionnaires. Remember, those who have reached the 48 and 60 month time points no longer need to complete any questionnaires.



From the beginning

Here we can see how recruitment has been building since POSNOC started back in July 2014. It's always reassuring to see that the line is ever rising. Can you plot yourself on the graph to see how many people had been recruited onto the study when you started?




Thank you for your time

This year will see the first few participants reach the final 5 year time point of the study. We would like to take this opportunity to thank you for your continued dedication and commitment to the study as without you it would not be possible. For those who have consented to receive the results of the study, this will occur once the last participant has reached the 5 years and all the data has been analysed. We currently expect this to be around 2027.



More new sites!



We are very excited to announce that since our last newsletter we have opened not one, not two, but three new recruiting sites! Back in February we opened Nuneaton's George Eliot hospital. Tameside General Hospital was then opened to recruitment in June and most recently Queen's Hospital Burton joined us in July. We would like to welcome all three new sites to the POSNOC team and we are sure they will all be a huge help in recruitment.

The Participant's Voice

At the beginning of the year Colleen, a POSNOC participant at Milton Keynes Hospital was featured on an ITV News feature, talking about her experience of the POSNOC Study and breast cancer. Well done Colleen!



We love to hear from you and are always looking to include your stories and experiences of the POSNOC study in the participant newsletter. In this edition, we have had the pleasure of hearing from Rosemary and are delighted to share with you her thoughts...



- Rosemary

"I like that the POSNOC study has a fairly laid back set up, no extra appointments at the hospital or extra tests. It is important to me that I can potentially help others in the future who experience this".

We are extremely excited to have heard from the first ever participant to be recruited onto the POSNOC study! Let's see what Jane has to say about her experience of the past 5 years:

"I am proud and delighted to be the first patient to finish the POSNOC trial following five years of excellent care from the team.

As far as I am aware results are looking positive, and I am so happy to have played a small part in helping to shape the way in which breast cancer is treated in the future."



- Jane



A message from the Chief Investigator:



Amit Goyal

"I would like to thank all participants for doing their bit to improve outcomes for future patients. Your continued contribution to the study by providing follow up data, filling questionnaires and staying in touch with the research team especially if you have moved will help in the analyses at the end of the study and provide results that will benefit patients globally."

And from the Australia and New Zealand Investigator:

"Australia and New Zealand sites remain committed to completing recruitment to POSNOC, and are pleased that accrual remains strong across our countries. We welcome Auckland Hospital as our 21st site.

We congratulate Amit and the team for their continued leadership of this very important trial."



Bruce Mann

Be heard...



We want you to be heard. If you have anything you want to tell us about your experiences or views of the study then we would love to hear from you. Please contact us via the details below if you'd like us to share your words on the POSNOC website or in the next newsletter.

Please be sure to get in touch with your local research team if you have any concerns about your treatment.

For any general trial queries please get in touch with your study coordinating team:



UK:

Nottingham Clinical Trials Unit
Email: POSNOC@nottingham.ac.uk

ANZ:

Breast Cancer Trials
breastcancertrials.org.au



www.posnoc.co.uk



Follow us on Twitter @POSNOC

#makelymphoedemahistory



This project is funded by the National Institute for Health Research (NIHR) (project reference 12/35/17). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Australian and New Zealand participation is supported by a grant from the National Health and Medical Research Council and the Breast Cancer Institute of Australia

FUNDED BY

NIHR | National Institute
for Health Research